Rob Shaw's most recent trade in Ultralife Corp was a trade of 4,000 Common Stock; $.10 par value done at an average price of $5.5 . Disclosure was reported to the exchange on May 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ultralife Corp | Robert W. Shaw | Director | Purchase of securities on an exchange or from another person at price $ 5.49 per share. | 14 May 2025 | 4,000 | 69,250 (0%) | 0% | 5.5 | 21,960 | Common Stock; $.10 par value |
| Acurx Pharmaceuticals Inc | Robert G. Shawah | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 145,500 | 145,500 | - | - | Stock Option | |
| Ultralife Corp | Robert W. Shaw | Director | Purchase of securities on an exchange or from another person at price $ 7.91 per share. | 12 Nov 2024 | 2,500 | 65,250 (0%) | 0% | 7.9 | 19,775 | Common Stock; $.10 par value |
| Acurx Pharmaceuticals Inc | Robert G. Shawah | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 145,000 | 145,000 | - | - | Stock Option | |
| Ultralife Corp | Robert W. Shaw | Director | Purchase of securities on an exchange or from another person at price $ 5.10 per share. | 07 Feb 2022 | 3,000 | 60,750 (0%) | 0% | 5.1 | 15,300 | Common Stock; $.10 par value |
| Acurx Pharmaceuticals Inc | Robert G. Shawah | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 200,000 | 200,000 | - | - | Stock Option | |
| Acurx Pharmaceuticals Inc | Robert G. Shawah | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 70,000 | 70,000 | - | - | Stock Option | |
| Ultralife Corp | Robert W. Shaw | Director | Purchase of securities on an exchange or from another person at price $ 7.12 per share. | 25 Feb 2021 | 1,750 | 57,750 (0%) | 0% | 7.1 | 12,460 | Common Stock; $.10 par value |
| Ultralife Corp | Robert W. Shaw | Director | Purchase of securities on an exchange or from another person at price $ 6.41 per share. | 19 Aug 2020 | 2,500 | 56,000 (0%) | 0% | 6.4 | 16,025 | Common Stock; $.10 par value |